Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale production

After mastering large‑scale mRNA manufacturing during the COVID‑19 pandemic, the sector is now turning its attention to delivering individualized vaccines to patients quickly.

The recent clinical success of Merck and Moderna’s intismeran autogene trial has heightened expectations for personalized mRNA cancer vaccines across the industry.

Intismeran is created by sequencing a patient’s tumor and healthy cells, identifying up to 34 unique neoantigens, and encoding them in an mRNA strand delivered by lipid nanoparticles to stimulate an immune response.

Moderna has cut the time from sample collection to vaccine administration to about six weeks, down from eight weeks in 2019, and analysts believe the process could be shortened to under a month.

The shift is described as “scaling out and scaling down,” focusing on flexible, rapid production rather than only mass manufacturing.